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Strengths and limitations of this study
 ► This observational study will assess comprehensive 
information about the long-term course of patients 
after acute pulmonary embolism and on the health-
care provided to these patients.
 ► Data are collected prospectively and systematically 
during the hospital stay and via postal question-
naires afterwards.
 ► The collection of biosamples in connection with so-
cioeconomic, clinical, treatment and outcome data 
will allow further research regarding different pa-
tient subgroups to improve primary and secondary 
prevention strategies.
 ► A limitation of the study is that analyses are not 
based on randomised treatment assignments.
 ► Another potential weakness could be the lost to fol-
low-up in the cohort, which may often lead to bias.
AbStrACt
Introduction Acute pulmonary embolism (PE) is a 
frequent life-threatening event and an important cause 
of hospitalisation, morbidity and mortality worldwide. 
Limited information on the long-term course of PE patients 
is available so far. The Lungenembolie Augsburg study 
will provide a view on the predisposing and PE-provoking 
factors, diagnostic procedures and short as well as 
long-term treatment options. Especially, the data on the 
long-term course of the disease—in combination with 
omics data obtained in biospecimens—will generate 
new knowledge regarding triggers, disease progression, 
treatment, long-term sequelae, prognosis and prevention 
of disease recurrence.
Methods and analysis In this prospective study, we will 
include about 1000 patients admitted to the university 
hospital of Augsburg, aged 18 years and older with a 
confirmed diagnosis of acute PE. At baseline, demographic 
information, symptoms on presentation, delay in diagnosis, 
predisposing and PE-provoking factors, comorbidity, quality 
of life, symptoms of anxiety and depression, information 
on invasive and non-invasive treatment procedures, 
complications and laboratory parameters will be collected. 
During the hospital stay, 30 mL blood will be collected from 
the patients, processed, aliquoted and frozen at −80°C. In 
a subgroup of patients, an eight-channel polygraphy will 
be carried out to assess sleep-disordered breathing. All 
study participants will be followed up for 60 months via 
postal questionnaires or telephone interviews after hospital 
discharge. Long-term survival, bleeding complications 
and PE recurrence during the follow-up are the primary 
study outcomes. To identify risk factors and determinants 
associated with these outcomes, confounder-adjusted 
Cox-regressions will be used for modelling and to estimate 
relative risks. Effect modification by age and sex will be 
examined.
Ethics and dissemination The study protocol was 
approved by the Ethics Committee of the Ludwig-
Maximilians-Universität München (Date of approval: 
1 August 2017, Reference number: 17-378). Study 
results will be presented at national and international 
conferences and published in peer-reviewed scientific 
journals.
IntroduCtIon
Acute pulmonary embolism (PE) is a frequent 
life-threatening event, and mostly a conse-
quence of deep vein thrombosis. It is the 
third most frequent cardiovascular syndrome 
after myocardial infarction and stroke1 2 and 
remains an important cause of hospitalisa-
tion, morbidity and mortality worldwide. In 
a prior study analysing WHO mortality data 
from 1998 to 2004, it could be shown that in 
most countries PE mortality decreased over 
time, but there was a continuous increase in 
Germany.3 Based on routine healthcare data, 
between 2005 and 2007, a total of 67 351, 
69 234 and 71 223 PE cases International Clas-
sification of Diseases-10th revision-Germany 
(ICD-10: I26) were documented yearly as 
the main or secondary diagnosis in German 
hospitals, respectively.4 The incidence of the 
disease rises with age and due to the ageing 
Western societies, it can be expected that a 
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larger number of patients will be diagnosed with PE in 
the future.5 Patients with PE have a case fatality rate of 
7%–11%, and approximately 10% of symptomatic PE 
cases are fatal within the first hour after symptom onset.6 7
The treatment of acute PE is usually inpatient with anti-
coagulants and possibly thrombolytic therapy. In patients 
in whom thrombolytic drugs are contraindicated, cath-
eter-assisted thrombus removal or surgical pulmonary 
embolectomy may be considered.8 After discharge, treat-
ment with anticoagulants is continued for at least three 
further months after the first episode of PE. In some 
conditions like PE recurrence, extended anticoagulant 
treatment is indicated. Nowadays non-vitamin K-depen-
dent oral anticoagulants (NOACs) are established for the 
treatment and secondary prophylaxis of acute PE.9
While prior studies mainly focused on the short-term 
outcomes, there is limited information on the long-term 
course of patients after acute PE. However, some obser-
vational studies and randomised cohorts reported a high 
long-term mortality. For example, in a retrospective study 
including more than 1000 persons with PE, Ng et al found 
an all-cause mortality rate of about 35% after a follow-up 
of 4 years.10 A recent meta-analysis of publications on the 
long-term consequences of LE showed that patients have 
to expect an increased risk of death (11%) and disease 
recurrence (6%) after primary therapy.11 Eighteen per 
cent had persistent right-ventricular dysfunction and 11% 
suffered from respiratory distress, which severely impairs 
performance in everyday life.11 The quality of life of 
patients with acute PE was significantly reduced compared 
with the general population11 and a more frequent onset 
of mental disorders such as depression, anxiety disorder 
and post-traumatic stress disorder was described as well.12 
It is unknown so far whether any particular treatment 
strategy can reduce these long-term outcomes and disease 
burden among patients with acute PE.
The Lungenembolie Augsburg (LEA) study will 
provide a view on the predisposing and provoking 
factors, comorbidity, diagnostic procedures, treatment 
options and the long-term course of PE. Furthermore, 
new knowledge regarding triggers, disease progression, 
treatment, long-term sequelae, prognosis and prevention 
of the disease will be generated by using information on 
omics data gained from different biological samples. The 
impact of predisposing factors for disease recurrence and 
comorbidities will be prospectively elucidated, helping 
to improve primary and secondary prevention strategies. 
In addition, the study will allow to assess subgroup differ-
ences regarding treatment effects and will contribute to 
our knowledge on patient outcomes such as long-term 
survival, bleeding complications and disease recurrence. 
Also, the evaluation of patient-oriented outcomes, such as 
quality of life and the burden of depression and anxiety 
disorders in PE patients, will be of advantage for the 
patients. Factors, which are associated with late recur-
rence of PE or long-term sequelae like chronic throm-
boembolic pulmonary hypertension (CTEPH), will be 
elucidated. This will help to identify patient subgroups 
who could potentially benefit from a long-term antico-
agulation therapy. Finally, with this observational study, 
knowledge about the safety and harm associated with the 
use of modern anticoagulation drugs in regular practice 
and in particular in cancer patients, who are usually not 
included in randomised control trials, will be generated. 
Thus, the study will provide a comprehensive view on 
the natural course of the disease and on the healthcare 
provided to patients with acute PE.
objECtIvES
Primary outcome
To estimate PE-related long-term survival, treatment-re-
lated bleeding complications, development of chronic 
thromboembolic pulmonary hypertension, and the 
frequency, circumstances and time points of PE recur-
rence. In particular, the association between inflamma-
tory biomarkers (eg, high-sensitive C reactive protein 
(hs-CRP) and disease outcomes will be investigated.
Secondary outcomes
1. To identify subgroups of PE patients (eg, patients with 
persistent right-ventricular dysfunction, high risk of PE 
recurrence or bleeding, patients under NOAC treat-
ment, etc) and to assess optimal treatment for these 
subgroups (in hospital and after discharge).
2. To examine the association between sleep-disordered 
breathing and nocturnal continuous positive airway 
pressure (CPAP) therapy and PE recurrence.
3. To evaluate the long-term health-related quality of life 
and the presence of anxiety and/or depression after 
PE.
4. To monitor the safety and harm associated with the 
use of specific treatments in hospital (eg, reperfusion 
treatment) and after discharge (secondary prevention, 
eg, the impact of direct oral anticoagulants).
5. To investigate the associations between metabolomics 
and proteomics and disease development as well as dis-
ease outcomes.
6. To determine the healthcare utilisation of patients 
with PE, and to determine differences in healthcare 
utilisation according to age, gender and socioeconom-
ic status.
7. To evaluate the currently used risk stratification pro-
cess for PE patients according to the European Society 
of Cardiology (ESC) guidelines, including the assess-
ment of right ventricular dysfunction.
MEthodS And AnAlySIS
The study aims to include all consecutive patients with inci-
dent as well as recurrent confirmed acute PE (diagnosis 
based on multidetector CT pulmonary angiography or 
ventilation–perfusion lung scanning) of adults admitted 
to the university hospital Augsburg. The study began on 
1 July 2017, and is expected to end on 31 December 2026 
(recruitment phase and follow-up).
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Participation in the study is voluntary, and irrespective 
of the management strategy and outcome. If a patient 
is willing to take part in the study, a written informed 
consent form has to be signed by him or her. In case a 
patient suffers from dementia or another disease with 
major restrictions, written informed consent will be 
signed by the responsible caregiver and a proxy interview 
will be conducted. The consent form is also provided in 
Turkish and Russian language, two very frequent popu-
lation groups in the Augsburg region. All other patients 
with language difficulties will be asked whether a rela-
tive is available for translating the consent form and 
answering the questions. In the university hospital Augs-
burg, the majority of PE patients of the study region will 
be treated, yearly about 300 cases. Based on the experi-
ence in previous comparable studies, it is expected that 
about 80%–90% of the patients will take part in the study. 
Data collection procedures will be performed in accor-
dance with the Declaration of Helsinki.
At the university hospital Augsburg trained study nurses 
prospectively record all confirmed cases with PE. In 
order to record all cases, an electronic list of suspected 
cases of PEs is compiled daily by the university hospital 
of Augsburg (inpatients and outpatients, also patients at 
the emergency department and intensive care unit). The 
study nurses then check and verify these suspected cases 
via the treating physicians. Patients with unsuspected 
PE on a regular CT are also included. There is a double 
read for all the tests for quality. The study nurses visit all 
patients to inform them about the study and to deliver 
the study documents. Patients will receive comprehensive 
and understandable information on the processes and 
consequences of the participation in the study.
data collection at baseline hospital stay
Patient interview and chart review
After the patients have given informed consent, the study 
nurses will interview the study participants during their 
hospital stay using a standardised questionnaire. The 
interviews will cover demographic information, symp-
toms on presentation, delay in diagnosis, predisposing 
and PE-provoking factors, comorbidities (eg, carcinoma, 
pulmonary and cardiac comorbidities, diabetes mellitus, 
neuromuscular disease, sleep-disordered breathing, etc). 
The patients will be asked to fill in self-administered 
questionnaires, including the EuroQol (EQ-5D),13 and 
the Hospital Anxiety and Depression Scale.14 During 
the hospital stay, routinely collected clinical data will be 
assessed by chart review; this includes information on 
comorbidities, PE-provoking factors (eg, immobilisation, 
trauma, surgery, thrombophilia and carcinoma), medi-
cations prescribed prior to PE and at hospital discharge, 
diagnostic procedures, location of thrombotic material, 
presence of deep vein thrombosis, prior PE, clinical 
parameters for disease severity (eg, right ventricular 
dysfunction, myocardial injury, etc), laboratory parame-
ters (routine parameters and biomarkers such as N-ter-
minal pro-brain natriuretic peptide, troponin), invasive 
and non-invasive treatment regimens as well as compli-
cations (eg, hypotension, cardiogenic shock, need of 
mechanical ventilation, rescue-thrombolysis, cardiac 
arrest, death, etc).
Substudy on sleep-disordered breathing
Recent research indicates that sleep-disordered breathing 
might be an independent risk factor for venous throm-
boembolism.15 However, it is still unknown if sleep-dis-
ordered breathing has any impact on the clinical course 
of PE or if nocturnal CPAP therapy can potentially 
prevent PE recurrence. Therefore, in a subgroup of 
patients, an eight-channel polygraphy (Mini Screen 
Plus, Heinen & Löwenstein, Bad Ems, Germany) will be 
carried out, measuring respiratory airflow, thoracic and 
abdominal breathing movements, pulse oximetry, pulse 
rate, snoring, body position and light. Polygraphy is a 
non-invasive, well-validated method for the diagnosis of 
sleep-disordered breathing, approved by health author-
ities and routinely performed at the university hospital 
Augsburg. The polygraphy measurements will be offered 
to all patients who are being treated for PE at the univer-
sity hospital of Augsburg in 2019 and 2020 and who will 
consent to the examination. The measurements will be 
conducted during hospital stay, when the patients are on 
the general ward. The examination will not prolong the 
patients’ hospital stay.
Collection of biomaterial
During the hospital stay, as soon as the patients are on 
the general ward, 30 mL blood will be collected from 
the patients in a fasting state. The blood samples will be 
processed and aliquoted into sample tubes at the Chair of 
Epidemiology, Ludwig-Maximilians Universität München, 
at UNIKA-T Augsburg. Thereafter, the aliquots will be 
frozen at −80°C and stored until laboratory analysis. 
Furthermore, from a subsample, that is patients with PE, 
who will be treated in the university hospital of Augsburg 
in 2020, 20 mL urine and a native as well as a stabilised 
stool sample will be collected and stored at −80°C.
It is planned to measure inflammatory markers (eg, 
hs-CRP), metabolomics and proteomics in blood samples. 
In urine and stool samples, metabolomics measurements 
(native stool samples) and 16SmRNA (V3/V4) micro-
biome sequencing (stabilised stool samples) will be 
conducted.
Follow-up of the PE patients
Morbidity follow-up and update of lifestyle and health factors
All study participants will regularly receive postal question-
naires or telephone interviews after hospital discharge (in 
the first year after 3, 6 and 12 months; thereafter every 
12 months). The postal questionnaire will contain ques-
tions on disease symptoms, comorbidity, health-related 
quality of life (Pulmonary Embolism Quality of Life Ques-
tionnaire,16 EQ-5D,13 anxiety and depression (Hospital 
anxiety and depression scale14), dyspnoea, major 
bleeding complications, recurrent events and healthcare 
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utilisation (readmissions, visits to physicians, clinics and 
emergency departments). Information on diet (repeated 
24 hours food list; Food-Frequency Questionnaire) and 
physical activity (German-Physical Activity Questionnaire 
PAQ-50+) will be gathered via standardised question-
naires. Data on current medication and treatment (eg, 
CPAP therapy) will be collected. Bleeding complications 
are classified as major if medical advice is needed. Recur-
rent PE is defined as the presence of any new pulmonary 
arterial clot obstruction after at least 3 months of suffi-
cient anticoagulation therapy.
An overview of the data collected at baseline and 
follow-up is given in table 1, and a study flow chart with 
enrolment and follow-up is depicted in figure 1.
Mortality follow-up
Regular mortality follow-ups will be performed using 
information from the residents’ registration offices in 
the study area. Causes of death will be extracted from the 
death certificates provided by the local health authorities 
in the study region and will be coded according to the 
ICD-10 (WHO).
Statistical analysis
After data cleaning, quality assurance and transformation 
of variables, descriptive statistics and explorative data anal-
ysis will be carried out to get an overview as well as basic 
information about the data. The formulated hypotheses 
and scientific questions will be examined according to a 
previously prepared statistical analysis plan.
Baseline characteristics will be presented as means±SD 
for normally distributed continuous variables and as 
median (IQR) for continuous variables without a normal 
distribution. Categorical variables will be expressed as 
percentages. Comparisons between two patient groups 
will be conducted using X²-test or Fisher’s exact test 
for categorical variables and the t-test for continuous 
variables.
Differences between at least three subgroups of PE 
patients, for example, related to their treatment and life-
style factors (categorised variables), will be investigated 
using log-linear models and analysis of variance. If there 
are any differences, post hoc tests will be used for identi-
fying them.
Primary outcome variables such as long-term survival, 
bleeding complications and PE recurrence will be avail-
able in a binary form as ‘yes/no’ variables. To identify risk 
factors and determinants associated with these outcome 
variables, confounder-adjusted Cox regression analysis 
will be used for modelling and to estimate relative risks. 
Effect modification by age and sex will be examined. To 
take account of competing risks of death when identi-
fying predictors for individual outcomes such as bleeding 
complications or PE recurrence, competing risk analysis 
will be conducted.
Basically, for continuous outcomes, multiple linear 
regressions will be used, if the assumptions regarding 
the residuals and the predictors are fulfilled. If necessary, 
the corresponding variables have to be transformed 
meanwhile.
All tests within the multivariable models will be 
conducted at an alpha level of 0.05. A correction of the 
significance level alpha will be made in case of multiple 
testing. All statistical analyses will be performed using SAS 
software 9.4 or R.
Sample size estimation
Every year, about 300 patients with acute PE receive in-hos-
pital treatment at the university hospital Augsburg. Based 
on the experience from previous studies, it is expected 
that 80%–90% of the patients will take part in the study. 
Consequently, it is planned to recruit about 250 study 
participants every year; altogether about 1000 patients 
will be included within 4 years. To determine whether this 
cohort size will be sufficient to achieve 80% probability of 
detecting a statistically significant difference in primary 
outcome (mortality) regarding the hs-CRP values during 
hospital stay. On the basis of a previous meta-analysis,11 
the investigators expect a proportion of deaths of 11% 
within a median follow-up of 18 months. With an esti-
mated effect estimate (HR) of 1.5, a variance of hs-CRP of 
0.7 and a rho²=0.36, the inclusion of at least 969 patients 
will be able to detect a significant difference with a statis-
tical power of 80% at a 5% significance level.
dissemination
Written informed consent is obtained from the study 
participants. Patients who do not consent will not be 
included. The study results will be presented at national 
and international conferences and published in peer-re-
viewed scientific journals.
Patient and public involvement
Public and patients were not involved in development 
of the study design, in recruitment of study participants 
or the implementation of the study. However, the study 
results will be discussed using focus groups consisting of 
patients and healthcare providers.
dISCuSSIon
The present manuscript describes the protocol for a 
prospective, observational cohort study designed to 
investigate the long-term course of patients treated for 
acute PE. Baseline data on lifestyle, predisposing factors, 
comorbidities, social variables, treatment procedures and 
complications are collected during hospital stay via face-
to-face interviews and extracting data from the medical 
records. Follow-up data will be assessed using postal ques-
tionnaires and mortality surveys.
Limitations of the study will be the lost to follow-up and 
the occurrence of missing data. Furthermore, a selection 
bias could be a concern, because it can be assumed that 
very ill patients will rather not take part in the study. In 
addition, analyses are not based on randomised treatment 
assignments. Finally, in contrast to existing multicentre 
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Occupation X X X X X
Smoking X X X X X
Alcolhol consumption X x x x x
Female health (pregnancy, childbirth…) X x x x x
(Prior) diseases X X X X X
Prior treatments X
Family history of PE X
Symptoms of PE X
Start of PE symptoms X
(Prior) medication X X X X X
Vital signs at hospital admission X
Physical activity X X X X X
Treatment-related variables X
  Date and time starting treatment prior 
admission
X
  Diagnostic procedures X
  Date and time of diagnosis X
  In-hospital treatment X
  In-hospital complications X
  Medication X
  Treatment (eg, thrombolysis) x
  Laboratory values X
General parameters   
  Date and time of hospital admission X
  Date hospital discharge X
Outcome parameters   
  Health-related quality of life   X X X X
  Mental health   X X X X
  Healthcare utilisation   X X X X
  Medication   X X X X
  Treatment (eg, CPAP)   X X X X
  Relapse   X X X X
  Bleeding complications   X X X X
  Chronic thromboembolic pulmonary 
hypertension
  X X X X
Dietary intake X X X X
CPAP, continuous positive airway pressure.
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Figure 1 Study flow diagram with enrolment and follow-up. 
FU, follow-up; PE, pulmonary embolism.
venous thromboembolism registries,17 the present study 
is designed as a single centre study. The strengths of the 
study are the prospective long-term collection of data, the 
large sample size and the comprehensive collection of 
data from the study participants. Another strength is the 
personal interview of patients about the acute event and 
the collection of biomaterials.
The LEA study will provide a comprehensive view on 
the long-term course of the disease and on the healthcare 
provided to patients with PE. It will generate knowledge 
about factors that may have an influence on the outcome 
and disease burden of PE patients. Thus, the results of 
the study can help clinicians in treating and guiding these 
patients.
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